Status new methods

CIPAC Methods, when proposed by a company or an organization get a first status (draft method) when they are discussed in a CIPAC Meeting. After having been accepted, they receive the status "provisional" in a following CIPAC Meeting, and finally they are accepted as full methods.

 

Decisions of the 64th CIPAC virtual meeting June 2020

 

The table "Decisions of the 64th CIPAC Meeting" presented below the methods which are either accepted as provisional or full methods. 

 CIPAC no. /
 name

Description Status  Published
 338 acephate The reversed phase HPLC method using internal standard (CIPAC/5207) for the determination of acephate in TC and SP formulations was accepted as a full CIPAC method, with the note that the method can also be used without the internal standard. full pre-published  
 method
 454 + 570
 alpha-
 cypermethrin +
 chlorphenapyr
The capillary GC method using internal standard (CIPAC/5220) for the determination of alpha-cypermethrin and chlorfenapyr in LN formulations was accepted as a full CIPAC method. full
pre-published  
 method
 91 atrazine The capillary GC method using internal standard (CIPAC/5215) for the determination of atrazine in TC, WG and SC formulations was accepted as a full CIPAC method, with the request to remove the data set obtained with the multi-method and inclusion of the HorRat values. full pre-published  
 method
 994 broflanilide The reversed phase HPLC method (CIPAC/5213) for the determination of broflanilide in TC and WP formulations was accepted as a full CIPAC method. full pre-published  
 method
 997
 cyetpyrafen
The reversed phase HPLC method (CIPAC/5191) for the determination of etpyrafen in TC and SC formulations was accepted as a full CIPAC method, with the note that the name should be modified to cyetpyrafen. full pre-published  
 method
 465
 hexaconazole
The reversed phase HPLC method (CIPAC/5209) for the determination of hexaconazole in TC, WG and SC formulations was accepted as a full CIPAC method. The HorRat values should be calculated and reported. full pre-published  
 method
 34 mancozeb The reversed phase HPLC method (CIPAC/5157) for the determination of mancozeb in TC and WP formulations was accepted as a full CIPAC method with some precisions in the description of the method. full pre-published  
 method
 737
 spirodiclofen
The reversed phase HPLC method (CIPAC/5195) for the determination of spirodiclofen in TC and SC formulations was accepted as a full CIPAC method. full pre-published  
 method
 MT 46.4
The harmonized accelerated storage procedure for all formulation types (CIPAC/5217) was accepted as a full CIPAC method. MT 46.4 supersedes all previous versions of MT 46 for accelerated storage. full pre-published  
 method
 616 florasulam
The reversed phase HPLC method (CIPAC/5257) for the determination of florasulam in TC and SC formulations was accepted as a provisional CIPAC method, with some additional editorial amendments in method description, inclusion of method for the determination of suspensibility for SC formulation.e provisional no
 283 metribuzin The capillary gas chromatographic method with split injection, using dipentylphthalate as internal standard and helium as eluent (CIPAC/5253), for the determination of metribuzin in TC, SC, WG and WP formulations was accepted as a provisional CIPAC method. It was proposed to consider the HorRat values resulted from the data sets using helium as eluent gas. provisional no
 641.202 quizalofop-P-ethyl The chiral phase HPLC method (CIPAC/5255) for the determination of quizalofop-P-ethyl in TC and EC formulations was accepted as a provisional CIPAC method, with additional modifications in the description of the method considering the selectivity of the column (using the right eluent) and inclusion of a second selective identity test. provisional no
 802 spinetoram The reversed phase HPLC method (CIPAC/5249) for the determination of spinetoram in TC, SC, WG, and DT formulations was accepted as a provisional CIPAC method pending on the amendments of the description of the method, inclusion of the identity tests, method for the determination of suspensibility for SC formulation, representative chromatograms. provisional no
 prothioconazole-desthio in prothioconazole formulations
The reversed phase HPLC method (ESI-MS/MS in MRM mode) for the determination of the relevant impurity prothioconazole-desthio in prothioconazole TC, SC, EC and FS formulations (CIPAC/5251) was noticed and adopted. adopted no